HAE related information from the Shire plc 2015 Annual Report:
- The $6 billion acquisition of Dyax expands and extends our industry-leading portfolio in HAE. With Dyax we bring into our portfolio DX-2930 (now SHP643). If approved, this therapy has the potential to expand HAE-treated patients and achieve worldwide sales of up to $2 billion with exclusivity beyond 2030.
- Our HAE portfolio, Cinryze and Firazyr, grew 23% and 22%, respectively.
- We also worked to strengthen our manufacturing position through renegotiation of our agreement with Sanquin. We are now in a position to seek a second source of supply to boost production of Cinryze.